Anti-pd1 antibodies and their use as therapeutics and diagnostics
AssigneeBeiGene Switzerland GmbH
InventorsKang LI, Tong ZHANG, Jing SONG, Lanlan XU, Qi LIU, Hao PENG
Life of this patent
Estimating the term…
Abstract
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Claims12
An antibody or antigen-binding fragment thereof that specifically binds to PD-1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain complementary determining region (CDR) 1 comprising amino acid residues 6-10 of SEQ ID NO:
- 31, a heavy chain CDR2 comprising SEQ ID NO:
- 32, a heavy chain CDR3 comprising amino acid residues 3-12 of SEQ ID NO:
- 33. a light chain CDR1 comprising SEQ ID NO:
- 34, a light chain CDR2 comprising SEQ ID NO:
- 35, and a light chain CDR3 comprising SEQ ID NO:
- 36.
An antibody or antigen-binding fragment thereof that specifically binds to PD-1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain complementary determining region (CDR) 1 comprising amino acid residues 1-8 of SEQ ID NO:
- 31, a heavy chain CDR2 comprising amino acid residues 2-8 of SEQ ID NO:
- 32, a heavy chain CDR3 comprising SEQ ID NO:
- 33. a light chain CDR1 comprising amino acid residues 4-9 of SEQ ID NO:
- 34, a light chain CDR2 comprising amino acid residues 1-3 of SEQ ID NO:
- 35, and a light chain CDR3 comprising SEQ ID NO:
- 36.
Dependencies are inferred from the claim text.